These experiments demonstrate that T cells, sensitized to tumor antigens in vivo, can be activated in vitro under conditions that promote hyperexpansion of either the CD4+ or CD8+ subset while retaining their potent therapeutic efficacy against established tumors. The gene discussed is CD4; the disease is neoplasm.